Videos and Podcasts

30th Apr 20

Pharmaxis to progress myelofibrosis drug to Phase II following positive results

Gary Phillips tells Proactive's Andrew Scott they're progressing to a phase II study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF). The move comes on the back of positive results from its phase 1b trial and long-term toxicity studies.

Watch interview

3rd Dec 19

Commsec Executive Series

Pharmaxis Ltd (PXS) MD, Gary Phillips speaks with Tom Piotrowski about the company’s broad pipeline of drug candidates, large licence deal with Boehringer & upcoming Phase 2 clinical results for NASH.

Watch interview

13th Aug 19

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine Bronchitol by Q1 2020


Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The company is confident it will meet information requirements for a Q1 2020 approval. Earlier this year, the FDA Pulmonary and Allergy Drug Advisory Committee (PADAC) released a positive vote that provides a clear path to meet this approval, subject to some further information being provided, which is now being undertaken and delivered.

The CEO also updated the market on the company’s deal with Boehringer for liver disease medicine, as well as its LOXL2 inhibitor program.

Watch interview